BWA
JANX icon

Basecamp Wealth Advisors’s Janux Therapeutics JANX Stock Holding History

Basecamp Wealth Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$906 Buy
59
+44
+293% +$637 ﹤0.01% 1535
2026
Q1 		$209 Sell
15
-1
-6% -$14 ﹤0.01% 1853
2025
Q4 		$221 Buy
+16
New +$376 ﹤0.01% 1695

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Basecamp Wealth Advisors's JANX Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Janux Therapeutics (JANX) stake by 293% in Q2 2026, buying an estimated $637 and bringing the position to 59 shares worth $906. The position accounts for ﹤0.01% of the portfolio, ranked #1535.

Basecamp Wealth Advisors first reported a position in JANX in Q4 2025 and has held it in 3 quarters since. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Basecamp Wealth Advisors held 59 shares of Janux Therapeutics worth $906 as of Q2 2026.
  • Basecamp Wealth Advisors bought 44 Janux Therapeutics shares in Q2 2026, an estimated $637.
  • Janux Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1535 holding.
  • Basecamp Wealth Advisors first reported a position in Janux Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.